摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-bis(2-((9Z,12Z)-octadec-9,12-dienoyloxy)ethyl)amine | 1346225-19-1

中文名称
——
中文别名
——
英文名称
N,N-bis(2-((9Z,12Z)-octadec-9,12-dienoyloxy)ethyl)amine
英文别名
2-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxyethylamino]ethyl (9Z,12Z)-octadeca-9,12-dienoate
N,N-bis(2-((9Z,12Z)-octadec-9,12-dienoyloxy)ethyl)amine化学式
CAS
1346225-19-1
化学式
C40H71NO4
mdl
——
分子量
630.008
InChiKey
KQVANBBLFJEBCK-MAZCIEHSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    13.2
  • 重原子数:
    45
  • 可旋转键数:
    36
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    64.6
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N,N-bis(2-((9Z,12Z)-octadec-9,12-dienoyloxy)ethyl)amine三乙胺 作用下, 以 二氯甲烷二甲基亚砜 为溶剂, 反应 17.03h, 生成 ((2-(3-(hydroxymethyl)azetidin-1-yl)acetyl)azanediyl)-bis(ethane-2,1-diyl) (9Z,9’Z,12Z,12’Z)-bis(octadeca-9,12-dienoate)
    参考文献:
    名称:
    IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    摘要:
    这项发明涉及可离子化的化合物,以及其组合物和使用方法。这些可离子化的化合物可用于制备纳米粒子组合物,用于生物制药和治疗。更具体地说,这项发明涉及提供纳米粒子以包裹活性剂,如核酸剂,并将活性剂传递和分发到细胞、组织、器官和受试者的化合物、组合物和方法。
    公开号:
    US20160376229A1
  • 作为产物:
    参考文献:
    名称:
    IONIZABLE COMPOUNDS AND COMPOSITIONS AND USES THEREOF
    摘要:
    这项发明涉及可离子化的化合物,以及其组合物和使用方法。这些可离子化的化合物可用于制备纳米粒子组合物,用于生物制药和治疗。更具体地说,这项发明涉及提供纳米粒子以包裹活性剂,如核酸剂,并将活性剂传递和分发到细胞、组织、器官和受试者的化合物、组合物和方法。
    公开号:
    US20160376229A1
点击查看最新优质反应信息

文献信息

  • LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS
    申请人:Nitto Denko Corporation
    公开号:US20130330401A1
    公开(公告)日:2013-12-12
    The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    该描述针对可用于增强脂质体中治疗剂传递的可电离脂质。
  • LIPID NANO PARTICLES COMPRISING COMBINATION OF CATIONIC LIPID
    申请人:KYOWA HAKKO KIRIN CO., LTD.
    公开号:US20140045913A1
    公开(公告)日:2014-02-13
    The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R 1 and R 2 are, the same or different, alkenyl, etc, and X 3 is absent or is alkyl, etc, X 1 and X 2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and Y 1 is absent or anion, L 1 is a single bond, etc, R 3 is alkyl, etc), and a cationic lipid represented by formula (II) (wherein: R 4 and R 5 are, the same or different, alkenyl, etc, and X 4 and X 5 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X 6 is absent or is alkyl, etc, Y 2 is absent or anion, a and b are, the same or different, 0 to 3, and L 4 is a single bond, etc, R 6 is alkyl, etc, L 2 and L 3 are —O—, —CO—O— or —O—CO—), and the like.
    本发明提供了一种脂质纳米粒子,可以使核酸轻松地进入细胞,包括由式(I)表示的阳离子脂质(其中:R1和R2是相同或不同的烯基等,X3不存在或是烷基等,X1和X2是氢原子,或结合在一起形成单键或亚烷基,Y1不存在或是阴离子,L1是单键等,R3是烷基等),以及由式(II)表示的阳离子脂质(其中:R4和R5是相同或不同的烯基等,X4和X5是氢原子,或结合在一起形成单键或亚烷基,X6不存在或是烷基等,Y2不存在或是阴离子,a和b是相同或不同的0到3,L4是单键等,R6是烷基等,L2和L3是—O—,—CO—O—或—O—CO—)等。
  • Lipids for Therapeutic Agent Delivery Formulations
    申请人:Nitto Denko Corporation
    公开号:US20160074514A1
    公开(公告)日:2016-03-17
    The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    本文描述了可离子化脂质,用于增强脂质体中治疗剂的传递。
  • NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP3275448A1
    公开(公告)日:2018-01-31
    The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.
    本发明提供了含核酸的脂质纳米颗粒,其中含有一种脂质(脂质 A),该脂质具有一个亲水单元,该亲水单元具有一个季铵基团和三个独立的任选取代的烃基、一种水溶性聚合物的脂质衍生物或脂肪酸衍生物以及一种核酸。
  • PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN
    申请人:Kyowa Hakko Kirin Co., Ltd.
    公开号:EP3301086A1
    公开(公告)日:2018-04-04
    The present invention relates to a method for producing a composition containing a complex between a membrane composed of a lipid monolayer (reversed micelle) and a nucleic acid, and a lipid membrane for encapsulating the complex therein, comprising the following steps A to D: Step A: preparing a complex between the nucleic acid and a liposome comprising a cationic lipid represented by the formula (I) and/or a cationic lipid other than cationic lipid represented by the formula (I); Step B: preparing a dispersion liquid by dispersing the complex in water or ethanol aqueous solution; Step C: preparing a solution by dissolving the formula (I) and/or the cationic lipid other than cationic lipid represented by the formula (I) in ethanol or an ethanol aqueous solution; and Step D: mixing the dispersion liquid and the solution, and optionally adding water; wherein the formula (I) is (wherein: R1 and R2 are, the same or different, each linear or branched alkyl, alkenyl or alkynyl having 12 to 24 carbon atoms, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, X3 is absent or is alkyl having 1 to 6 carbon atoms, or alkenyl having 3 to 6 carbon atoms, when X3 is absent, Y is absent, a and b are 0, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, and L1 and L2 are -O-, Y is absent, a and b are, the same or different, 0 to 3, and are not 0 at the same time, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, or alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-, Y is absent, a and b are, the same or different, 0 to 3, L3 is a single bond, R3 is a hydrogen atom, and L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-, or Y is absent, a and b are, the same or different, 0 to 3, L3 is -CO- or -CO-O-, R3 is alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms substituted with 1 to 3 substituent(s), which is(are), the same or different, amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, or dialkylcarbamoyl, wherein at least one of the substituents is amino, monoalkylamino, dialkylamino, or trialkylammonio, and L1 and L2 are , the same or different, -O-, -CO-O- or -O-CO-, and when X3 is alkyl having 1 to 6 carbon atoms or alkenyl having 3 to 6 carbon atoms, Y is a pharmaceutically acceptable anion, a and b are, the same or different, 0 to 3, L3 is a single bond, R3 is alkyl having 1 to 6 carbon atoms, alkenyl having 3 to 6 carbon atoms, L1 and L2 are, the same or different, -O-, -CO-O- or -O-CO-).
    本发明涉及一种生产含有由脂质单层(反向胶束)组成的膜与核酸之间的复合物的组合物以及用于将复合物包封在其中的脂质膜的方法,包括以下步骤A至D: 步骤 A:制备核酸与由式(I)代表的阳离子脂质和/或除式(I)代表的阳离子脂质以外的阳离子脂质组成的脂质体之间的复合物; 步骤 B:将复合物分散于水或乙醇水溶液中,制备分散液; 步骤 C:将式(I)和/或式(I)代表的阳离子脂质以外的阳离子脂质溶解在乙醇或乙醇水溶液中,制备溶液;以及 步骤 D:混合分散液和溶液,可选择加水; 其中式 (I) 为 (其中 R1 和 R2 相同或不同,各自为具有 12 至 24 个碳原子的直链或支链烷基、烯基或炔基、 X1 和 X2 为氢原子,或结合在一起形成单键或亚烷基、 X3 不存在或为具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基、 当 X3 不存在时 Y 不存在,a 和 b 为 0,L3 为单键,R3 为具有 1 至 6 个碳原子的烷基、具有 3 至 6 个碳原子的烯基、或具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基,这些取代基相同或不同,为氨基、单烷基氨基、二烷基氨基、三烷基氨基、羟基、烷氧基、氨基甲酰基、单烷基氨基甲酰基或二烷基氨基甲酰基,且 L1 和 L2 为 -O-、 Y 不存在,a 和 b 相同或不同,为 0 至 3,且同时不为 0,L3 为单键,R3 为具有 1 至 6 个碳原子的烷基、具有 3 至 6 个碳原子的烯基,或具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基被 1 至 3 个取代基取代、L1和L2是相同或不同的氨基、单烷基氨基、二烷基氨基、三烷基氨基、羟基、烷氧基、氨基甲酰基、单烷基氨基甲酰基或二烷基氨基甲酰基,-O-、-CO-O-或-O-CO-、 Y 不存在,a 和 b 是相同或不同的 0 至 3,L3 是单键,R3 是氢原子,L1 和 L2 是相同或不同的 -O-、-CO-O- 或 -O-CO-,或 羟基、烷氧基、氨基甲酰基、单烷基氨基甲酰基或二烷基氨基甲酰基,其中至少一个取代基是氨基、单烷基氨基、二烷基氨基或三烷基氨基,且 L1 和 L2 是相同或不同的 -O-、-CO-O- 或 -O-CO-,以及 当 X3 是具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基时,Y 是药学上可接受的阴离子,a 和 b 是相同或不同的 0 至 3,L3 是单键,R3 是具有 1 至 6 个碳原子的烷基或具有 3 至 6 个碳原子的烯基,L1 和 L2 是相同或不同的-O-、-CO-O-或-O-CO-)。
查看更多